June 2024 in “Military medicine” JAK inhibitors like baricitinib and ritlecitinib are effective new treatments for severe alopecia areata.
Baricitinib may effectively treat oral lichen planus.
January 2024 in “Drug Discoveries & Therapeutics” Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
November 2023 in “Journal of Investigative Dermatology” JAK inhibitors partially restore scalp bacteria balance in alopecia areata patients.
September 2023 in “Journal of the American Academy of Dermatology” Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
November 2022 in “Journal of Investigative Dermatology” The lotion with specific plant extracts effectively increased hair growth and improved hair cycle in subjects after 3 months.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
JAK inhibitors show promise in treating moderate to severe alopecia areata.
October 2021 in “International Journal of Dermatology” JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.
January 2016 in “Hair transplant forum international” Topical JAK inhibitors may help treat hair loss.
November 2020 in “Journal of The American Academy of Dermatology” Oral JAK inhibitors help regrow hair in alopecia patients.
182 citations,
December 2017 in “Journal of the American Academy of Dermatology” Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
83 citations,
June 2017 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help children with alopecia areata regrow hair.
21 citations,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” There is no cure for alopecia areata, but treatments like JAK inhibitors show promise.
12 citations,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
2 citations,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
1 citations,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Treating alopecia areata is difficult due to limited approved treatments, but new therapies like JAK inhibitors show promise.
1 citations,
November 2017 in “Dermatologic therapy” JAK inhibitors show promise as a future treatment for hair loss.
1 citations,
November 2016 in “Saengmyeong gwahag hoeji/Saengmyeong gwahak hoeji” New treatments for the autoimmune hair loss condition alopecia areata may include JAK inhibitors and other immunomodulators.
December 2024 in “International Journal of Dermatology” JAK inhibitors may help treat both alopecia areata and vitiligo, but more research is needed.
December 2024 in “Dermatological Reviews” New treatments for Alopecia Areata, like JAK inhibitors, are effective, and future research is exploring advanced therapies.
April 2024 in “Expert opinion on investigational drugs” JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
March 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
August 2023 in “JAAD international” Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
May 2023 in “Journal of managed care & specialty pharmacy” Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.
April 2023 in “Revista colombiana de reumatología” JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.